Antisense and RNAi Therapeutics Market
Antisense and RNAi Therapeutics Market Research Report 2024: Global Market to Reach $3.6 Billion by 2030 - Investments in RNA-Based Research Expands the Market for Novel Therapeutic Approaches
19. November 2024 10:53 ET | Research and Markets
Dublin, Nov. 19, 2024 (GLOBE NEWSWIRE) -- The "Antisense and RNAi Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...
North American RNA Therapeutics Market
North America RNA Therapeutics Market Research 2024-2029: Revolutionary Advancements in RNA Technology and Personalized Medicine Propel Growth
14. November 2024 05:21 ET | Research and Markets
Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "North America RNA Therapeutics Market, By Country, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ...
Antisense & RNAi Therapeutics Market
Antisense & RNAi Therapeutics Market Overview 2024-2030 - Global Antisense & RNAi Therapeutics Market Forecast to Reach $14.4 Billion by 2030
12. November 2024 05:33 ET | Research and Markets
Dublin, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The "Antisense & RNAi Therapeutics - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering.The global market for...
e-therapeutics_primary_logo.png
e-therapeutics Announces Business Updates and Interim Results
31. Oktober 2024 09:00 ET | e-therapeutics plc
LONDON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced business...
RNAZ White background cropped.jpg
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
17. September 2024 07:00 ET | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
22157.jpg
RNAi Market and Technologies Industry Report 2024, with Company Profiles of Major Players including Alnylam Pharmaceuticals, Novartis, Thermo Fisher Scientific and Revvity
23. August 2024 04:02 ET | Research and Markets
Dublin, Aug. 23, 2024 (GLOBE NEWSWIRE) -- The "RNAi Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.The global market for RNAi technology is estimated to...
ADARx Pharmaceuticals Appoints Ajim Tamboli, CFA as Chief Financial Officer
30. Juli 2024 09:05 ET | ADARx Pharmaceuticals
ADARx Pharmaceuticals Appoints Ajim Tamboli, CFA as Chief Financial Officer
Logo Resized for Globe Newswire2.jpg
Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing
12. Juni 2024 08:30 ET | Wave Life Sciences USA, Inc.
Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave’s INHBE program as a best-in-class approach for...
Phio.jpg
Phio Pharmaceuticals Secures New Investor
17. Mai 2024 09:00 ET | Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
Phio.jpg
Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)
16. Mai 2024 08:00 ET | Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...